The biotechnology company Galapagos has raised 300 USD in fresh money from American investors, via the issuing of new shares, it said Thursday. The Mechelen company issued 2,575,107 new shares, at the price of 116.50 dollars per share.
The Bel 20 company announced Wednesday that its Filgotinib, a drug for rheumatism, has performed well in the phase III study, which facilitates a future commercialization.
The Brussels Times
